Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Scott

Podiatrist, Foot & Ankle Surgery Phoenix, AZ Doctor of Podiatric Medicine

NPI 1053554600 CMS profile 92824

9321 W Thomas Rd Ste 205, Phoenix, AZ 85037

Open in the dashboard

General payments

$1,127,567

892 records reported · program years 2019–2025

Research payments

$6,939

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,108 paid to institutions, not to them · program year 2025

Through program year 2025, Ryan Scott of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,127,567 across 892 general payments and $6,939 in research payments paid to them. Separately, studies naming them as principal investigator received $1,108 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $268,180 218
2024 General $208,757 169
2023 General $215,437 159
2022 General $195,584 122
2021 General $106,647 82
2020 General $45,824 48
2019 General $87,138 94
2019 Research $6,939 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Scott
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Ryan Scott were reported at $268,180. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Ryan Scott Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $87,138 $389 $118–$1,406 $163
2020 $45,824 $191 $62–$691 $114
2021 $106,647 $329 $104–$1,341 $132
2022 $195,584 $419 $125–$1,611 $149
2023 $215,437 $377 $128–$1,164 $160
2024 $208,757 $394 $134–$1,168 $164
2025 $268,180 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $575,577 483 payments
  2. International Life Sciences $293,906 27 payments
  3. Medline Industries, Inc. $128,214 61 payments
  4. Anika Therapeutics, Inc. $55,576 39 payments
  5. Wright Medical Technology, Inc. $43,702 50 payments
  6. Parcus Medical, LLC $10,967 4 payments
  7. Amniox Medical, Inc. $6,660 5 payments
  8. Trice Medical, Inc. $5,181 10 payments
  9. Paragon 28, Inc. $1,135 6 payments
  10. Avanos Medical $1,104 9 payments
  11. Other $5,543 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $512,343 127 payments
  2. Royalty or License $482,068 39 payments
  3. Travel and Lodging $77,900 232 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,716 20 payments
  5. Food and Beverage $22,895 469 payments
  6. Honoraria $600 2 payments
  7. Gift $46 3 payments
Products named General payments · program years 2019–2025
  1. FLEXBAND $184,390 6 payments
  2. FLEXBAND Orthopaedics $184,174 24 payments
  3. MEDLINE UNITE $162,297 32 payments
  4. PROSTEP $143,541 91 payments
  5. ORTHOLOC 2 LAPIFUSE $129,602 76 payments
  6. INFINITY $67,198 52 payments
  7. PROPHECY $67,058 64 payments
  8. T2 $60,527 2 payments
  9. SALVATION $51,563 20 payments
  10. INBONE $50,558 58 payments
  11. Other $639,300 669 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. TissueTech, Inc. $6,158 1 payment
  2. Wright Medical Technology, Inc. $780 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

603

Median for Podiatry: 160

Drug cost

$6,140

Median for Podiatry: $2,368

Branded share of claims

20.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 52 $1,305
Gabapentin Generic 55 $872
Ondansetron Hcl Generic 114 $815
Meloxicam Generic 100 $629
Methylprednisolone Generic 81 $615
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 75 $525
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $446
Diclofenac Sodium Generic 13 $353
Ibuprofen Generic 11 $248
Pregabalin Generic 22 $224

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$96,440

Of which drugs: $258

Medicare patients

260

Average age 72

Services billed

1,451

169 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 68%
Chronic kidney disease 23%
Depression 23%
Diabetes 22%
Ischemic heart disease 20%
Cancer 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 50 360 $257

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Nubeqa
$8 — —
Xofigo
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

900 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record